NASDAQ:XCUR Exicure (XCUR) Stock Price, News & Analysis $7.05 -0.08 (-1.12%) Closing price 08/1/2025 03:56 PM EasternExtended Trading$8.34 +1.29 (+18.23%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Exicure Stock (NASDAQ:XCUR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Exicure alerts:Sign Up Key Stats Today's Range$6.71▼$7.3750-Day Range$5.55▼$10.8052-Week Range$1.44▼$36.00Volume307,006 shsAverage Volume42,680 shsMarket Capitalization$44.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. Read More Exicure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreXCUR MarketRank™: Exicure scored higher than 19% of companies evaluated by MarketBeat, and ranked 862nd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Exicure. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Exicure is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exicure is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExicure has a P/B Ratio of 6.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Exicure's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.16% of the float of Exicure has been sold short.Short Interest Ratio / Days to CoverExicure has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exicure has recently increased by 417.35%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldExicure does not currently pay a dividend.Dividend GrowthExicure does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.67 Percentage of Shares Shorted6.16% of the float of Exicure has been sold short.Short Interest Ratio / Days to CoverExicure has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exicure has recently increased by 417.35%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment-0.50 News SentimentExicure has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Exicure this week, compared to 1 article on an average week.Search Interest1 people have searched for XCUR on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Exicure to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Exicure insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.90% of the stock of Exicure is held by insiders.Percentage Held by Institutions42.82% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exicure's insider trading history. Receive XCUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exicure and its competitors with MarketBeat's FREE daily newsletter. Email Address XCUR Stock News HeadlinesExicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous TransplantAugust 1 at 4:17 PM | businesswire.comXCUR | Exicure Inc. Annual Cash Flow Statement - MarketWatchJuly 19, 2025 | marketwatch.comOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.August 2 at 2:00 AM | InvestorPlace (Ad)Is Exicure Stock (XCUR) Experiencing a Dead Cat Bounce?June 30, 2025 | msn.comExicure Shares Up After Swing to Profit in 1QJune 27, 2025 | marketwatch.comExicure, Inc. Reports First Quarter 2025 Financial ResultsJune 27, 2025 | businesswire.comExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-QMay 28, 2025 | businesswire.comWhy Exicure Inc. (XCUR) Soared on MondayApril 22, 2025 | msn.comSee More Headlines XCUR Stock Analysis - Frequently Asked Questions How have XCUR shares performed this year? Exicure's stock was trading at $13.67 at the beginning of 2025. Since then, XCUR shares have decreased by 48.4% and is now trading at $7.05. How were Exicure's earnings last quarter? Exicure, Inc. (NASDAQ:XCUR) posted its quarterly earnings results on Friday, June, 27th. The company reported ($0.45) EPS for the quarter. When did Exicure's stock split? Exicure shares reverse split before market open on Tuesday, August 27th 2024.The 1-5 reverse split was announced on Monday, August 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Exicure? Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Exicure own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exicure investors own include Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Tesla (TSLA), Meta Platforms (META), NIO (NIO), Viking Therapeutics (VKTX) and Energy Transfer (ET). Company Calendar Last Earnings6/27/2025Today8/02/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XCUR CIK1698530 Webwww.exicuretx.com Phone(847) 673-1700FaxN/AEmployees50Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.70 million Net MarginsN/A Pretax Margin-1,938.60% Return on Equity-219.60% Return on Assets-82.03% Debt Debt-to-Equity RatioN/A Current Ratio2.91 Quick Ratio2.91 Sales & Book Value Annual Sales$500 thousand Price / Sales89.11 Cash FlowN/A Price / Cash FlowN/A Book Value$1.12 per share Price / Book6.29Miscellaneous Outstanding Shares6,320,000Free Float6,072,000Market Cap$44.56 million OptionableNot Optionable Beta3.67 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:XCUR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.